Fennec Pharmaceuticals Inc (FRX.TO) has seen a notable decline in its stock price this week despite reporting strong fiscal results.
Fennec Pharmaceuticals Inc's stock closed at C$13.62, reflecting a 0.14% decrease for the day and a 2.62% decline over the past week. This comes after the company announced record net product sales for fiscal year 2025, which might have influenced investor sentiment.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$508.12M
52W high
$17.64
52W low
$7.59
1W change
-2.62%
Beta
1.23
Analyst Price Targets
Based on analyst covering FRX · as of Sep 17, 2026
Wall Street analysts forecast FRX stock price to rise 546.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+546.6% Upside
Current Price
C$14.47
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
52.6%
Annualized
90-Day Vol
58.4%
Annualized
Trend (90d)
-0.9%
Annualized drift
90d Mean
C$14.43
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.46 | C$12.06 – C$17.33 |
| 60 trading days | C$14.44 | C$11.17 – C$18.66 |
| 90 trading days | C$14.43 | C$10.54 – C$19.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Fennec Pharmaceuticals reported impressive sales growth, the stock's recent performance suggests cautious investor sentiment, potentially influenced by the company's recent share offering and leadership changes.
Fennec Pharmaceuticals Reports Record FY2025 Net Product Sales of $44.6M
The 75% increase in Q4 sales year-over-year highlights the company's growth potential, even as the stock faces downward pressure.
Bull case
The company reported a remarkable 50% increase in net product sales year-over-year, indicating strong demand for its product, PEDMARK®. This positive momentum could attract long-term investors looking for growth opportunities in the healthcare sector.
Bear case
Despite strong sales, the stock has faced volatility and a significant drop over the past month. The recent pricing of a public offering may dilute existing shareholders' value, raising concerns among investors.
Price Action Overview
Fennec Pharmaceuticals Inc (FRX.TO) has experienced a slight downturn in its stock price, closing at C$13.62, down 0.14% for the day and 2.62% over the past week. The stock is down 15.38% over the past month, although it has gained 39.00% year-to-date.
Recent Company News
Advertisement
Fennec Pharmaceuticals recently reported record fiscal year 2025 net product sales of C$44.6 million, marking a 50% increase year-over-year. The fourth-quarter sales reached C$13.8 million, a significant 75% increase from the same quarter last year. Despite these positive results, the company also announced an underwritten public offering of 4,666,667 common shares at C$7.50 per share, which may have contributed to investor caution.
Technical Picture
Currently, Fennec Pharmaceuticals' stock is trading below its 50-day moving average of C$15.79, indicating a bearish trend in the short term. The stock is above its 200-day moving average of C$12.51, suggesting a more favorable long-term outlook. The 52-week range for the stock is C$7.59 to C$17.64, with the current price reflecting approximately 60% of this range. The stock's beta of 1.23 indicates it is more volatile than the broader market.
Insider Activity
There have been no reported insider transactions for Fennec Pharmaceuticals in the recent period, suggesting stability in the company's leadership amidst its ongoing business developments.
Price Action Summary
As of the last close, Fennec Pharmaceuticals Inc's stock was C$13.62, reflecting a 1D change of -0.14%. Investors are advised to monitor upcoming developments closely as the company navigates its growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
